Stockscreener 앱 받기
1.69
0.60%
0.01
시간 외 거래:
1.69
전일 마감가:
$1.68
열려 있는:
$1.64
하루 거래량:
1.21M
Relative Volume:
5.33
시가총액:
$27.16M
수익:
-
순이익/손실:
$-8.29M
주가수익비율:
-2.4143
EPS:
-0.7
순현금흐름:
$-6.47M
1주 성능:
+5.62%
1개월 성능:
+18.18%
6개월 성능:
+50.89%
1년 성능:
-20.28%
1일 변동 폭
$1.54
$1.70
1주일 범위
$1.46
$1.70
52주 변동 폭
$0.94
$2.55
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
NNVC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.69 | 25.72M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
What analysts say about NanoViricides Inc. stockFree Market Dynamics Reports - Autocar Professional
NanoViricides Inc. Stock Analysis and ForecastExceptional stock performance - Autocar Professional
Measles Now Has a DrugNV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides - Lansing State Journal
NanoViricides says lead antiviral boosted survival in measles-infected mice - Proactive financial news
Breakthrough: New Drug NV-387 Could Be First-Ever Treatment for Measles as Global Cases Surge - Stock Titan
What drives NanoViricides Inc. stock priceBreakneck growth rates - jammulinksnews.com
Is NanoViricides Inc. a good long term investmentFree Market Volatility Navigation Tips - jammulinksnews.com
Mpox Antiviral Clinical Trial Advances as WHO Extends Global Emergency - Global Biodefense
WHO Extended Global Emergency Status of MPox EpidemicDevelopment of Treatment for MPox with NV-387 is Timely, Says NanoViricides - Great Falls Tribune
NanoViricides Advances MPox Treatment Development Amid WHO's Extended Health Emergency - citybuzz -
NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency - Proactive financial news
D.C. United Roofing Inc. Wins 2025 Consumer Choice Award for Roofing in Barrie - The Palm Beach Post
NanoViricides Targets Multi-Billion MPox Market with Superior Treatment as WHO Extends Global Emergency - Stock Titan
Go Industries Inc. Unveils Durable Winch Grille Guard for Unmatched Vehicle Protection - The Palm Beach Post
How NanoViricides Inc. stock performs during market volatilityFree Best Stocks to Buy Today - Newser
What makes NanoViricides Inc. stock price move sharplyReal Time Breakout Tracking - Newser
Why NanoViricides Inc. stock attracts strong analyst attention3x Return Stock Radar - Newser
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks - Proactive financial news
Small cap wrap: Lisata Therapeutics, Uranium American Resources, Nano One Materials... - Proactive financial news
Market movers: Autodesk, Waters, NanoViricides... - Proactive financial news
NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox - Zacks Small Cap Research
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides - Worcester Telegram
NanoViricides nears completion of clinical trial design for MPox treatment - Proactive financial news
Dallas Central's Welborn Garage Receives 2025 Consumer Choice Award for Garage & Overhead Doors - The Palm Beach Post
Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape - Stock Titan
Folsom Homeowners Rejoice: All Pro Overhead Garage Doors Elevates Garage Door Opener Repair Services - Sarasota Herald-Tribune
Wealth Enhancement Advisory Services LLC Invests $26,000 in NanoViricides, Inc. (NYSE:NNVC) - Defense World
Helios Secures $4M Seed Round to Build First AI-Native Operating System for Public Policy Professionals - The Palm Beach Post
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Milwaukee Journal Sentinel
New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Asbury Park Press
PrivateJet.com Launches a New Era in On-Demand Luxury Air Travel - The Arizona Republic
MicroGenDX Transforms Infectious Disease Diagnostics With Innovative 24-Hour Testing Technology - The Daily Jeffersonian
Will Scott Presented “5 Key Insights for Mastering Generative Engine Optimization” at SMX Advanced Boston - Daily Commercial
NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case - The Globe and Mail
NanoViricides (NYSE:NNVC) Trading Up 0.7% – Still a Buy? - Defense World
NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox - Proactive Investors
Keathley Landscaping Leads Sod Installation Companies in Wylie with Expert Services - The Palm Beach Post
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate - Worcester Telegram
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):